高リスク患者におけるクロストリディオイデス・ディフィシル感染症の再発を予防する新しい生生物療法製品であるEXL01の評価 (LIVEDIFF)
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.
Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.
In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.
Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.
Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.
The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Nicolas BENECH, MD
- 電話番号:+33 04 26 10 94 35
- メール:nicolas.benech@chu-lyon.fr
研究連絡先のバックアップ
- 名前:Fanny JOUBERT
- 電話番号:+33 04 26 73 27 27
- メール:Fanny.joubert@chu-lyon.fr
研究場所
-
-
-
Annecy、フランス
- まだ募集していません
- CH Annecy Genevois Service de Maladies infectieuses
-
コンタクト:
- Emilie PIET, MD
- 電話番号:+33 450636602
- メール:epiet@ch-annecygenevois.fr
-
主任研究者:
- Emilie PIET, MD
-
Clermont-Ferrand、フランス、63003
- 募集
- Service d'hépato-gastroentérologie - CHU Estaing
-
コンタクト:
- Julien SCANZI, MD
- 電話番号:04 73 75 02 35
- メール:jscanzi@chu-clermontferrand.fr
-
主任研究者:
- Julien SCANZI, MD
-
Grenoble、フランス
- 募集
- CHU Grenoble Service Maladies infectieuses et tropicales
-
コンタクト:
- Salomé GALLET, MD
- 電話番号:+33 476763947
- メール:sgallet@chu-grenoble.fr
-
主任研究者:
- Salomé GALLET, MD
-
Lille、フランス
- 募集
- CHU Lille Unité des Maladies Infectieuses et tropicales
-
コンタクト:
- Sarah STABLER, MD
- 電話番号:+33 320445743
- メール:sarah.stabler@chu-lille.fr
-
主任研究者:
- Sarah STABLER, MD
-
Lyon、フランス、69004
- 募集
- Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
-
コンタクト:
- Nicolas BENECH, MD
- 電話番号:+33 04 26 10 94 35
- メール:nicolas.benech@chu-lyon.fr
-
主任研究者:
- Nicolas BENECH, MD
-
コンタクト:
- Emma SANDOZ
- 電話番号:+33 04 26 73 28 62
- メール:emma.sandoz@chu-lyon.fr
-
Marseille、フランス
- 募集
- APHM La Timone Service de Maladies infectieuses
-
コンタクト:
- Nadim CASSIR, MD
- メール:nadimshams.cassir@ap-hm.fr
-
主任研究者:
- Nadim CASSIR, MD
-
Paris、フランス、75012
- 募集
- Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
-
コンタクト:
- Paul MCLELLAN, MD
- 電話番号:+33 01 49 28 20 00
- メール:Paul.mclellan@aphp.fr
-
主任研究者:
- Paul MCLELLAN, MD
-
Saint-Etienne、フランス、42100
- 募集
- Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
-
コンタクト:
- Elisabeth BOTHELO-NEVERS, Pr
- 電話番号:+33 04 77 12 77 89
- メール:elisabeth.botelho-nevers@chu-st-etienne.fr
-
主任研究者:
- Elisabeth BOTHELO-NEVERS, Pr
-
Toulouse、フランス、31059
- 募集
- Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
-
主任研究者:
- Laurent ALRIC, Pr
-
コンタクト:
- Laurent ALRIC, Pr
- 電話番号:05 61 32 37 54
- メール:Alric.l@chu-toulouse.fr
-
Valence、フランス、26000
- 募集
- Service de Maladies Infectieuses - CH de Valence
-
コンタクト:
- Amélie DUREAULT, MD
- 電話番号:+33 04 75 75 75 71
- メール:adureault@ch-valence.fr
-
主任研究者:
- Amélie DUREAULT, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adult patient ≥18 years of age
-
≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:
- Age ≥70 years
- Chronic renal failure (haemodialysis or GFR<60ml/min
- History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
- ≥3 CDI in the last 12 months (including current episode)
- CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
-
On current or planned vancomycin treatment per os
-
Patient able to give free, informed and written consent
-
Enrolled in compulsory national social security scheme
Exclusion Criteria:
- Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
- Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
- Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
- Cirrhosis with Child C score
- Hospitalization in continuing care unit or intensive care unit
- Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
- Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
- Inflammatory bowel disease
- Proven uncontrolled celiac disease
- Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
- major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
- Antibiotic therapy in progress or planned during the study for an infection other than CDI
- Surgery scheduled during the study requiring perioperative antibiotics.
- -Women without contraception*, pregnant or breastfeeding women
- History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
- History of hypersensitivity to vancomycin as mentioned in local prescribing information.
- Personal history of fecal microbiota transplantation < 6 months
- Persons deprived of liberty by judicial or administrative decision
- Adults under legal protection or unable to give consent
- Swallowing disorders making oral treatment impossible
- Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
- Expected life expectancy of less than 6 months
- Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
- Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
- History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
- Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:パート A (オープンラベル EXL01)
|
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
|
|
実験的:パートB (EXL01)
|
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
Following a at least 10-days vancomycin treatment : Oral EXL01 including:
|
|
プラセボコンパレーター:パート B (プラセボ)
|
Following a at least 10-days vancomycin treatment: Oral placebo including:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events
時間枠:at Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment |
at Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
時間枠:at Week 8
|
Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment. |
at Week 8
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
時間枠:at Week 8
|
Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI. |
at Week 8
|
|
Evaluation of the safety and tolerability profile of oral EXL01
時間枠:at Week 2, Week 4, Week 8, Week 16
|
Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events |
at Week 2, Week 4, Week 8, Week 16
|
|
Number of stools per day over the past 24 hours
時間枠:at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
時間枠:at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Digestive symptoms are measured at each visit using the stool calendar |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
時間枠:at Week 8, Week 16
|
Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ) |
at Week 8, Week 16
|
|
Number of stools per day over the past 24 hours
時間枠:at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
時間枠:at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Digestive symptoms are measured at each visit using the stool calendar |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
時間枠:at Week 8, Week 16
|
Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ) |
at Week 8, Week 16
|
|
Assessment of patient quality of life during treatment and follow-up
時間枠:At Week 8 and Week 16
|
Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI) |
At Week 8 and Week 16
|
|
Assessment of recurrence of C. difficile infection
時間枠:At Week 16
|
Phases I and II percentage of patients with recurrence of C. difficile infection at M4 |
At Week 16
|
|
Evaluation of the presence of EXL01 in the fecal microbiota
時間枠:At Week 8
|
Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0 |
At Week 8
|
|
Assessment of EXL01 persistence in the intestinal microbiota
時間枠:At Week 0 and Week 16
|
Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0 |
At Week 0 and Week 16
|
|
16S rRNA sequencing or shotgun
時間枠:at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Gut microbiota composition at each visit |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
16S rRNA sequencing or shotgun
時間枠:at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Gut microbiota composition at each visit |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
時間枠:at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission |
at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
時間枠:at Week 0, Week 2, Week 4, Week 8, Week 16
|
Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission |
at Week 0, Week 2, Week 4, Week 8, Week 16
|
|
Assessment of recurrences of C. difficile infection requiring hospitalization
時間枠:At Week 8
|
phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8 |
At Week 8
|
|
Assessment of recurrences of C. difficile infection requiring hospitalization
時間枠:at Week 16
|
phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4 |
at Week 16
|
|
Assessment of recurrences of C. difficile infection requiring surgery
時間枠:at Week 8
|
phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8 |
at Week 8
|
|
Assessment of recurrences of C. difficile infection requiring surgery
時間枠:at Week 16
|
phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4 |
at Week 16
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Nicolas BENECH, MD、Hospices Civils de Lyon
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 69HCL22_0980
- 2023-506232-32-00 (その他の識別子:EU CT Number)
- 2023 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。